Patient Access February 7, 2019 Specialty Pharmacy Patient Status Data Quality Challenges and Solutions 4 Minute Read Without visibility into each individual patient journey, your specialty brand cannot consistently intervene to help patients overcome barriers to therapy initiation and adherence. Today, the poor quality of specialty...
Contracts & Pricing December 12, 2018 Looking to 2019 from the Life Sciences Trade and Channel Strategic... 2 Minute Read In this post IntegriChain Senior Vice President of Sales, Gary Palgon, shares the trending topic's from the 2018 CBI Life Sciences Trade & Channel conference held in Philadelphia, Pa...
Patient Access December 10, 2018 Five Steps to a Better Specialty Pharmacy Data Contracting Strategy 4 Minute Read An effective specialty data contracting strategy starts at the finish line and works backward. The decisions made in terms of data fields, sub-status granularity, reporting frequency, and contact language,...
Distribution September 26, 2018 Frequently Asked Questions – 340B Program 4 Minute Read The 340B program is subject to increasing scrutiny as pharmaceutical manufacturers search for solutions to identify and act on non-compliance such as diversion and duplicate discounts. This post is...
Channel August 20, 2018 Opioid Crisis Exposes Vulnerabilities in Suspicious Order Monitoring 4 Minute Read The American opioid crisis exposed gaps in the reporting systems designed to flag suspicious orders of pharmaceutical products classified as controlled substances. Pharmaceutical manufacturers are now facing increased scrutiny...
Patient Access August 3, 2018 3 Key Opportunities to Improve Specialty Patient Initiation 3 Minute Read There are several ways specialty brands can improve patient initiation by implementing data-driven patient support strategies. Successful interventions to streamline patient initiation have the potential to speed Time to...
Managed Services July 27, 2018 The Economics of Rare Disease and Implications for Payer Contract Strategy 3 Minute Read Rare diseases affect 30 million people in the United States, which roughly equates to 10% of the population. In 2017, 40% of the novel drugs approved by the FDA...
